Proto-Oncogene Proteins B-raf

• 

  Subject Areas on Research

  • A Multivariate Computational Method to Analyze High-Content RNAi Screening Data. 
  • A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. 
  • Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). 
  • BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. 
  • BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. 
  • BRAF polymorphisms and the risk of ovarian cancer of low malignant potential. 
  • Beta2 adrenergic receptor activation stimulates pro-inflammatory cytokine production in macrophages via PKA- and NF-kappaB-independent mechanisms. 
  • Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment? 
  • Clinical correlates of NRAS and BRAF mutations in primary human melanoma. 
  • Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles. 
  • Colon cancer, version 3.2014. 
  • Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. 
  • Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors. 
  • Copper is required for oncogenic BRAF signalling and tumorigenesis. 
  • Dangerous liaisons: flirtations between oncogenic BRAF and GRP78 in drug-resistant melanomas. 
  • Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma. 
  • Elution profile analysis of SDS-induced subcomplexes by quantitative mass spectrometry. 
  • Epac1-induced cellular proliferation in prostate cancer cells is mediated by B-Raf/ERK and mTOR signaling cascades. 
  • Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). 
  • Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. 
  • Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. 
  • Exposure to flame retardant chemicals and occurrence and severity of papillary thyroid cancer: A case-control study. 
  • Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. 
  • Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). 
  • Histological and molecular evaluation of patient-derived colorectal cancer explants. 
  • Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile. 
  • Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. 
  • LGR5 is associated with tumor aggressiveness in papillary thyroid cancer. 
  • Melanoma brain metastasis: overview of current management and emerging targeted therapies. 
  • Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells. 
  • Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. 
  • Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults. 
  • Mutations of the BRAF gene in human cancer. 
  • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. 
  • Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma. 
  • Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract. 
  • Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. 
  • Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. 
  • Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. 
  • The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • McCall, Shannon Jones, Associate Professor of Pathology, Pathology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics